Dosimetry Data from Ph 3 COMPETE Trial Supports Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with GEP-NETs

“As the first company to conduct dosimetry in a large, randomized Phase 3 radiopharmaceutical trial in patients with Grade 1 or 2 GEP-NETs, we are encouraged by these findings, which align with the favorable therapeutic and safety profile of ¹⁷⁷Lu-edotreotide observed in our COMPETE trial,” said Dr. Andrew Cavey, chief executive officer of ITM. “This important dosimetry work would not have been possible without the support and cooperation of the investigators and, most importantly, the patients who participated in the trial.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib